Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)

PHASE2CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Acute Heart Failure
Interventions
DRUG

Liraglutide

Active Drug

DRUG

Placebo

Placebo

Trial Locations (25)

17603

Lancaster Heart and Stroke Foundation, Lancaster

19104

University of Pennsylvaina, Philadelphia

19107

Jefferson Medical College, Philadelphia

19140

Temple University Hospital, Philadelphia

19718

Christiana Care Health Services, Newark

21287

Johns Hopkins Hospital, Baltimore

27705

Duke University, Durham

28538

Southeast Regional Medical Center, Lumberton

30322

Emory University School of Medicine, Atlanta

44106

University Hospitals- Case Medical Center, Cleveland

44109

Metro Health System, Cleveland

44195

Cleveland Clinic, Cleveland

55905

Mayo Clinic, Rochester

60611

Northwestern University, Chicago

63110

Washington University, St Louis

63117

Saint Louis University Hospital, St Louis

77030

Michael Debakey VA Medical Center, Houston

84132

University of Utah School of Medicine, Salt Lake City

Utah VA Medical Center, Salt Lake City

84157

Intermountain Medical Center, Murray

02111

Tufts Medical Center, Boston

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

02132

Boston VA Healtcare System, West Roxbury

05401

The University of Vermont- Fletcher Allen Health Care, Burlington

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Duke University

OTHER